ストックスクリーナーアプリを入手
70.61
0.44%
-0.31
アフターアワーズ：
70.61
Bio Techne Corp (TECH) 最新ニュース
Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Activist investor Ananym urges Bio-Techne to consider selling - MSN
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com
List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn
Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com
TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus
TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus
$64.99 support anchors Bio-Techne stock near current levels - Traders Union
Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com
TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus
German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian
Is Bio-Techne stock underperforming the S&P 500? - MSN
Germany's Merck to buy Bio-Techne for $73 per share - MSN
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN
Germany's Merck to buy Bio-Techne for $11.3 billion - MSN
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN
Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
TECH Maintained by Baird -- Price Target Raised to $73.00 - GuruFocus
TECH Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion - MSN
Enterprise value to revenue forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Bio-Techne Corporation Actuals & Estimates (NASDAQ:TECH) - TradingView
Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools - Oncodaily
Taxation With Representation: Sidley, Paul Weiss, Kirkland - Law360
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH) - PR Newswire
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership - leadersleague.com
TECH Downgraded by Stephens & Co. -- Price Target Raised to $73. - GuruFocus
Merck KGaA Acquires Bio-Techne Corporation for 11.3 Billion Dollars - HarianBasis.co
Deutsche Bank cuts Bio-Techne stock rating on Merck acquisition By Investing.com - Investing.com Nigeria
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout - Citeline News & Insights
Bio-Techne Corporation (TECH) Merck KGaAM&A CallSlideshow (NASDAQ:TECH) 2026-06-26 - Seeking Alpha
Stephens Downgrades Bio-Techne to Equal Weight From Overweight, Adjusts Price Target to $73 From $68 - marketscreener.com
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout - Yahoo Finance
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets - marketscreener.com
Merck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocks - MSN
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Raises Price Target to $73 From $66 - marketscreener.com
Merck KGaA's Bio-Techne Deal Seems a Strong Fit -- Market Talk - Moomoo
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $66 - marketscreener.com
Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain CircumstancesSEC Filing - TradingView
Bio-Techne (TECH) Sees Significant Price Surge - GuruFocus
Merck KGaA (MKGAF) Acquires Bio-Techne (TECH) for $73 per Share - GuruFocus
Merck to buy Bio-Techne (NASDAQ: TECH) in $73 per share all-cash deal - Stock Titan
Bio-Techne retention bonuses approved for Kim Kelderman, Jim Hippel - TradingView
Merck Pulls Off Biggest Deal in a Decade With $11.3 Billion Bio-Techne Acquisition - finance.biggo.com
5 Stocks Winning by Double Digits - Insider Monkey
Deutsche Bank cuts Bio-Techne stock rating on Merck acquisition - Investing.com
William Blair downgrades Bio-Techne stock rating on Merck acquisition By Investing.com - Investing.com South Africa
William Blair downgrades Bio-Techne stock rating on Merck acquisition - Investing.com UK
Merck to acquire Bio-Techne for $11.3bn, expanding bioprocessing and cell therapy capabilities - Manufacturing Chemist
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal - The Daily Upside
Merck KGaA to acquire Bio-Techne for $11.3 billion in cash - Investing.com South Africa
Germany’s Merck to boost lab-tools business with $11 billion Bio-Techne deal - MSN
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):